- Elevance Health declared an unchanged $1.72 quarterly dividend, annualizing to $6.88 per share and a forward ELV dividend yield of about 1.75%.
- The September 10 ex-dividend date has passed, meaning new ELV buyers will not receive the September 25 payment.
- ELV dividends are supported by a 23% payout ratio and at least 15 consecutive annual increases, though medical costs and policy risks remain important.
September dividend deadline has passed
Elevance Health declared a $1.72 quarterly dividend, with the $1.72 per-share payment due September 25. The September 10 ex-dividend date has already passed, so investors buying ELV now will not receive this month’s distribution.
The unchanged ELV dividend annualizes to $6.88 per share. At ELV’s recent price of $393.54, that equals a forward dividend yield of approximately 1.75%.
That yield is not high compared with many income stocks or government bonds. ELV’s appeal is instead its potential to compound income over time through dividend increases and share-price recovery.
ELV dividends retain a long growth record
Elevance has increased its dividend every year since 2011, establishing at least 15 consecutive annual raises. Its payment-based dividend growth rate stands at 2.7% over one year, 7.5% over three years, and roughly 10.5% annually over five and 10 years.
The recent slowdown in growth deserves attention, but a modest increase is not necessarily a warning sign for an insurer navigating higher healthcare utilization and policy uncertainty. More importantly, the reported 23% payout ratio leaves room for reinvestment, debt management, buybacks, and future payout growth.
ELV’s 12.3 Chowder number, combining current yield and five-year dividend-growth rate, also suggests a reasonable balance between present income and long-term growth.
Defensive business faces policy risks
Health insurance can provide recurring premium revenue and resilience when economic conditions weaken. Elevance serves about 45 million medical members and operates across commercial insurance, Medicare, Medicaid, pharmacy benefits, and healthcare-services businesses.
This diversification can reduce reliance on any single customer group or product line. However, investors should closely monitor reimbursement trends, medical-cost ratios, and regulatory developments, particularly in Medicare Advantage and Medicaid.
Higher treatment utilization, drug costs, or unfavorable government reimbursement changes could pressure earnings and limit the pace of future ELV dividend raises.
Valuation supports a dividend-growth case
Shares trade at roughly 17.4 times trailing earnings, near the company’s cited historical valuation range. The stock is about 10% below its 52-week high of $436.24, while the supplied blended fair-value estimate of $401.27 indicates limited near-term upside.
For dividend investors, ELV fits best as a dividend-growth holding rather than a high-current-yield purchase. Its low payout ratio, long raise streak, and healthcare exposure support dividend durability, although medical-cost volatility, debt concerns, and government-program risk remain relevant.
